24
2020-11
Kintor Pharmaceutical Limited announced that the Company’s Suzhou Industrialisation Base was granted the Pharmaceutical Production License issued by Jiangsu Medical Products Administration.
29
2020-10
Kintor Pharmaceutical's COVID-19 Clinical Trials for Proxalutamide to expand Patient Enrolment
Kintor Pharmaceutical Limited is delighted to announced that the clinical trial of anti-androgen treatment Proxalutamide for the novel coronavirus disease (COVID-19) has reached the initial target of 381 patients enrolment on 25 October 2020.
27
2020-10
Kintor Pharmaceutical has been successfully selected as the excellent case of the advanced enterprises in 2020 science and technology Innovation of the People.cn upon provision of comments and recommendations by experts.
16
2020-10
On 16 October 2020, Kintor Pharmaceutical Limited (Stock code: 9939, “Kintor Pharmaceutical”) announced that it has entered into a strategic cooperation agreement on biological drug development with Pumis Pharmaceutical Co., Ltd (“Pumis”).
30
2020-09
Kintor Pharmaceutical Signs Strategic Cooperation Agreement with MabPlex
On 30 September 2020, Kintor Pharmaceutical Limited announced that Kintor Pharmaceutical entered into a strategic cooperation agreement with MabPlex International Ltd. , pursuant to which both parties will carry out all-round cooperation on the research and development and production in biological macromolecular drugs.
17
2020-09
Acne Drug KX-826 Gel Approved for Clinical Trials in China
On 17 September 2020, Kintor Pharmaceutical Limited is pleased to announce that it has received clinical trial approval from the National Medical Products Administration for the gel dosage form of KX-826 for the treatment of acne and androgenetic alopecia.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn